Litcius/Paper detail

Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series

Stacy D. D’Andre, Sean D. McAllister, Jasdeepa Nagi, Karthik V. Giridhar, Eduardo Ruiz-Macias, Charles L. Loprinzi

2021Integrative Cancer Therapies27 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Chemotherapy-induced peripheral neuropathy is a common and often severe side effect from many chemotherapeutic agents, with limited treatment options. There is no literature on the use of topical cannabinoids for chemotherapy-induced neuropathy. CASE PRESENTATIONS: The current manuscript presents a case series of patients presenting in oncology clinics at Sutter Health, CA and Mayo Clinic, Rochester, MN from April 2019 to December 2020 with chemotherapy-induced peripheral neuropathy who used topical creams containing the cannabinoids delta-nine-tetrahydrocannabinol (THC) and/or cannabidiol (CBD). CONCLUSIONS: This case series suggests that topical cannabinoids may be helpful for patients with chemotherapy-induced peripheral neuropathy. This paper also discusses the potential mechanisms of action by which topical cannabinoids might alleviate established CIPN symptoms. A randomized placebo-controlled trial using a standardized product is planned to study the actual efficacy of such treatment.

Topics & Concepts

Chemotherapy-induced peripheral neuropathyMedicineCannabidiolPeripheral neuropathyChemotherapyRandomized controlled trialDelta-9-tetrahydrocannabinolCannabisInternal medicineOncologyCannabinoidPsychiatryEndocrinologyReceptorDiabetes mellitusCannabis and Cannabinoid ResearchCancer Treatment and PharmacologyChemotherapy-related skin toxicity
Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series | Litcius